| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| OREX has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Weight Loss Products & Services | 24 |
$500 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Orexigen Therapeutics Inc | 40 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Orexigen Therapeutics | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | OREXIGEN THERAPEUTICS INC (OREX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | OREXIGEN THERAPEUTICS INC (OREX=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: OREXIGEN THERAPE -- OREX | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: FOLD , BHRT , BNVI , HALO , OPTR , OREX , RNN , VNDA -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Directors Deals Ltd. | Company Snapshot | Company Snapshot - Orexigen Therapeutics Inc | 1 |
$10 |
1.48% Nasdaq 
Research Reports
